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Dose-response of compression therapy for chronic
venous edema—higher pressures are associated
with greater volume reduction: Two randomized
clinical studies
Wolfgang Vanscheidt, MD,a Alexandra Ukat, MD,a and Hugo Partsch, MD,bFreiburg, Germany; and
Vienna, Austria
Background: Two phase II clinical studies used an experimental, multi-chambered compression device with different cuff
pressure combinations in subjects with leg edema and chronic venous insufficiency. The objective of each study was to
evaluate the safety and the relative effects of different cuff pressure combinations to determine if edema reduction was
dose-dependent.
Methods: Each study enrolled adults with chronic (>6 weeks) venous edema corresponding to CEAP C3-C5. The test
device could apply different pressures at the foot, gaiter, mid-calf, and upper-calf. In the first study, the following six
sustained pneumatic compression (SPC) profiles were applied for six hours each: 20, 30, and 40-mmHg at the gaiter with
graduated SPC (ie, lower pressures at the calf); and 20, 30, and 40-mmHg at the gaiter with nongraduated SPC (ie, the
same pressures at the calf). In the second study, the following three intermittent pneumatic compression (IPC) profiles
were applied for two hours each: 40, 50, and 60-mmHg at the gaiter with graduated IPC (ie, lower pressures at the calf).
Each study included a baseline profile with no compression and two-day intervals between profiles. Leg volume was
measured before and after compression using the water-displacement method.
Results:A dose-response relationship was observed between increased SPC/IPC pressures and reduced limb edema. Limb
volume was reduced most effectively with the highest pressures of 40-mm Hg nongraduated SPC and 60-mm Hg
graduated IPC (136 mL and 87 mL, respectively); however, some subjects reported discomfort with these profiles. Limb
volume was reduced by more than 100 mL with 30 to 40-mm Hg graduated SPC and by 69 mL with 50-mm Hg
graduated IPC, and subjects rated these profiles as comfortable or very comfortable. Of the 28 study participants (12
SPC, 16 IPC), two subjects reported pain with 60-mmHg IPC; no other adverse events were reported with SPC or IPC.
Conclusion: Pneumatic compression was safe and well-tolerated, with a dose-response relationship between increased
SPC/IPC pressures and reduced leg edema. To our knowledge, this is the first study to demonstrate a dose-relationship
in compression therapy: higher pressures are associated with greater volume reduction in subjects with chronic venous
edema. (J Vasc Surg 2009;49:395-402.)The most important clinical consequence of chronic
venous insufficiency (CVI) is venous leg ulcers,1 which are
associated with significant morbidity and cost.2 Venous leg
ulcers are the most prevalent form of chronic wounds,
accounting for up to 80% of all leg ulcers in the Western
world.2 Thus, adequate management of CVI may have
substantial clinical implications for chronic wound care.
Standard care of CVI includes appropriate compression
therapy in patients with an ankle brachial pressure index
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doi:10.1016/j.jvs.2008.08.0700.8 to treat edema and promote venous return.3 Pneu-
matic compression reduces venous stasis by promotion
of return venous blood flow.2 Some studies suggest that
pneumatic compression also enhances fibrinolytic activ-
ity,4 although other studies have challenged this conclu-
sion.5
Bandages or stockings are used for static compres-
sion therapy, but there is considerable variation in the
type of compression.6 Furthermore, it is not possible to
accurately adjust the pressure gradient applied by these
devices. Additionally, uncontrolled variation in applied
gradient can occur over time with limb shape change; for
example, as edema in the limb decreases, the pressure on
the limb from the compression device subsequently de-
creases. Several clinical studies have reported that inter-
mittent pneumatic compression (IPC) of the legs in
addition to stockings or bandages improves healing of
venous ulcers and alleviates symptoms in patients with
CVI without ulcers, but a systematic review of the avail-
able evidence concluded that the data could not be relied
on to inform the optimal choice of compression therapy
or optimal protocol for patients with CVI or venous
395
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vices and decreasing pressure gradients from ankle to
thigh may be more effective than single-pressure, one-
chambered models at achieving the desired “milking”
pattern, but comparative data on multi- and single-
chambered devices are lacking.7
Given the potential advantages of adding IPC to
provide precise regulation of limb compression, it is
important to know which compression profiles reduce
edema most effectively. Hypothetically, greater com-
pression should provide greater reduction of edema, but
surprisingly up to now there have been no clinical studies
to firmly establish this relationship. This report describes
two phase II clinical studies of an experimental, multi-
chambered compression device that used several differ-
ent cuff pressure combinations. The objective of each
study was to evaluate the safety and the relative effects of
different cuff pressure combinations to determine if
edema reduction was dose-dependent.
METHODS
Two separate phase II studies were conducted. Inclu-
sion criteria for each study were at least 18 years of age
(with an upper limit of 80 years of age in the study of
sustained pneumatic compression), chronic (6 weeks) leg
edema, CVI for at least 6 weeks (CEAP classification C3–
C5; Ep,s; As,d; Pr), refluxes greater than 0.5 seconds in at
least one major venous segment assessed by Duplex, and
ankle-brachial pressure index 0.8 to treat edema. Key
exclusion criteria were active leg ulcer (C6), compression
therapy during the prior 48 hours, deep vein thrombosis in
the last six months, active cardiac disease or significant
history of cardiac disease, edema-reducing therapy, or an-
ticoagulant therapy. Informed consent was obtained for all
subjects, and each study was approved by an Independent
Ethics Committee.
The Physiological Test Device was a battery-operated
experimental unit that used inflatable pneumatic cuffs to
Table I. Pressure profiles studied
Pressure profile Foot
SPC study
No compression NA
20 mm Hg graduated 10
30 mm Hg graduated 20
40 mm Hg graduated 30
20 mm Hg nongraduated 10
30 mm Hg nongraduated 20
40 mm Hg nongraduated 30
IPC study
No compression NA
40 mm Hg graduated 40
50 mm Hg graduated 50
60 mm Hg graduated 60
IPC, Intermittent pneumatic compression;NA, not applicable (no compressapply controlled compression to the foot and calf. It con-sisted of three main elements: a foot cuff, a calf cuff, and an
electronic control/user-interface unit. The three elements
were linked together by pneumatic tubing to form one
complete functional unit. The cuffs contained four separate
air bladders, one in the foot cuff and three in the calf cuff, that
allowed different pressures to be applied independently to the
foot, gaiter, mid-calf, and upper-calf. The user interface al-
lowed graduated pressures to be entered into the electronic
control unit. Pressure transducers in the pneumatic supply
system ensured that accurate pressures were delivered and
could be monitored and maintained throughout testing. The
use of battery power to operate the device allowed subject
mobility during testing. However, subjects were instructed to
remain seated as much as possible during study treatment to
reduce the potential influence of ambulation on study assess-
ments.
During pneumatic compression therapy, the test device
was applied to the more edematous leg and the contralat-
eral leg was used as a control. The device was used in
conjunction with an associated sock that was worn between
the limb and the inflatable cuffs. Subjects did not wear any
other compression stockings/devices except the study de-
vices. After each profile and device removal, the subject was
allowed 10 minutes rest sitting down before efficacy mea-
surements.
Previous data on the optimal pressure profile were not
available, so the test profiles were selected on the basis of
clinical experience to be consistent with currently available
devices. In the sustained pneumatic compression (SPC)
study, subjects completed an observation-only profile and
were randomized to treatment with the following seven
profiles (Table I): one profile each with 20, 30, and 40 mm
Hg SPC at the gaiter and the same pressures at the calf
(nongraduated SPC); and one each with 20, 30, and 40
mm Hg SPC at the gaiter and lower pressures at the calf
(graduated SPC). All subjects completed the non-treat-
ment profile first; thereafter, randomization determined
Pressure, mmHg
Gaiter Mid-calf Upper-calf
NA NA NA
20 10 0
30 20 10
40 30 20
20 20 20
30 30 30
40 40 40
NA NA NA
40 35 30
50 45 40
60 55 50
vice was applied during this period); SPC, sustained pneumatic compression.the order in which each subject was treated with the six
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pressures at the foot than at the gaiter. Each SPC profile was
administered for 6 hours with at least 48 hours between
profiles.
In the IPC study, subjects completed an observation-
only profile and were randomized to treatment with the
following three profiles (Table I): one profile each with 40,
50, and 60 mm Hg at the gaiter, the same pressures at the
foot, and lower pressures at the mid-calf and upper-calf
(graduated IPC). Each IPC profile was administered for
two hours with at least 46 hours between profiles.
In each study, the volumes of the test leg and untreated
leg were measured at the start and end of application of
each profile by the water immersion technique.8,9 The
subject stood and immersed one leg into a boot-shaped
device filled with water at 30°C. The weight of water
displaced was recorded with a precision scale and was
converted to the volume of water displaced, and thus, the
volume of the leg, using the conversion 1 g 1 mL (ie, the
Archimedes principle). This procedure was then repeated
with the other leg.
At the start and end of each profile, the investigator
reported whether ankle edema was present and whether
skin condition was normal. At the end of study visits
when the device was used (ie, all study visits except the
observation-only profile), the subject categorized the
profile as very comfortable, comfortable, uncomfortable,
or very uncomfortable. Adverse events were recorded at
each study visit.
Data that were collected only in the SPC study included
leg circumference measurements at the start and end of
each profile at the minimum girth of the ankle, at the
maximum girth of the calf, just below the tibial tuberosity,
and at the middle of the foot. Changes in toe systolic
pressure and transcutaneous oxygen pressure (TcpO2)
were collected only in the IPC study, which used higher
pressures and was designed and conducted after the SPC
study.
The primary safety outcome was the incidence of all
reported adverse events during the study period. The
number and percentage of subjects with adverse events,
serious adverse events, discontinuations due to adverse
event, related adverse events, severity of adverse events,
and deaths were summarized by term. The primary effi-
cacy outcome was change in limb volume. Absolute
changes and percentage changes in limb volume from the
start to the end of each profile were compared between
the test profiles and the observation-only profile. Rela-
tive reduction of limb volume was calculated as the
change in the test leg minus the change in the untreated
leg. Secondary efficacy outcomes included relative
change in circumference at the ankle, at the mid-foot,
below the tibial tuberosity, and at the calf; skin condition
at the end of each profile; device comfort for each profile;
and shift tables for the presence of ankle edema at the
start and end of each profile.RESULTS
SPC study. All 12 subjects enrolled in the SPC study
were included in the safety and efficacy populations, and all
subjects completed treatment. Baseline demographic and
clinical characteristics are summarized in Table II.
No adverse events were reported in this study. Edema
was not reported as an adverse event, but it was observed in
the ankle area not covered by the sleeve for two (17%)
subjects with the 40-mm Hg nongraduated SPC profile
and one (8%) subject with the 30-mm Hg graduated SPC
profile. One (8%) subject developed skin irritation with
20-mmHg graduated SPC. Subjects usually rated SPC as
comfortable or very comfortable with each of the profiles
(Fig 1), but three (25%) subjects reported discomfort at least
once with the following profiles: one subject reported discom-
fort with 30- to 40-mm Hg nongraduated SPC and 20-mm
Hg graduated SPC; and the other two subjects reported
discomfort only with 40-mm Hg nongraduated SPC.
Dose-dependent reductions of leg volume were ob-
served with SPC therapy (Fig 2). The volume of the test leg
increased by 12 mL relative to the untreated leg when no
compression was administered during the observation-only
profile. In contrast, 20- to 40-mm Hg of SPC reduced the
volume of the test leg relative to the untreated leg during
Table II. Baseline demographic and clinical
characteristics
SPC study
(n  12)
IPC study
(n  16)
Gender, n (%)
Male 5 (42) 5 (31)
Female 7 (58) 11 (69)
Age, years
Mean  SD 60.8  11.31 64.4  12.67
Median (min, max) 61.0 (38, 78) 64.0 (43, 79)
Duration of venous
insufficiency, years
Mean  SD 18.9  9.44 21.0  7.17
Median (min, max) 20.0 (3, 30) 20.5 (5, 31)
Clinical classification, n (%)
C3 – Edema 3 (25) 1 (6)
C4 – Skin changes without
ulceration 7 (58) 13 (81)
C5 – Skin changes with
healed ulceration 2 (17) 2 (13)
Etiologic classification, n (%)
EP – Primary 12 (100) 13 (81)
ES – Secondary 0 3 (19)
Ankle branchial pressure
index, mmHg
Mean  SD 1.03  0.08 1.05  0.06
Median (min, max) 1.0 (0.9, 1.1) 1.1 (0.9, 1.1)
Anatomical distribution of
reflux, n (%)
Superficial 8 (67) 7 (44)
Deep 0 3 (19)
Both 4 (33) 6 (38)
IPC, intermittent pneumatic compression; SPC, sustained pneumatic com-
pression.each profile, with a dose-dependent range of 44 mL to 106
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nongraduated SPC, respectively. These differences were
statistically significant (P  .011) for the 30 to 40 mm Hg
graduated SPC profiles and the 20 to 40 mm Hg non-
graduated SPC profiles compared with the observation-
only profile.
Mean reductions of circumference during SPC (Table III,
online only) appeared to be dose-dependent at the ankle, calf,
and tibial tuberosity; circumference reduction in the treated
leg relative to the untreated leg at these locations was progres-
sively greater as the SPC pressure increased. Circumference
reduction at the foot during SPC was not dose-dependent. All
subjects had improvement with edema from the observation-
only profile to the last treatment profile, including marked
improvement in eight (67%) subjects.
IPC study. All of the 16 subjects enrolled in the IPC
study were included in the safety and efficacy populations,
and all subjects completed the study treatment. Baseline
demographic and clinical characteristics of the study partic-
ipants are summarized in Table II.
There were 15 (94%) subjects with normal skin
throughout treatment and one (6%) subject with lipo-
dermatosclerosis at baseline had “other” skin condition
at every assessment. All subjects reported the 40-mm Hg
and 50-mm Hg graduated IPC profiles were comfortable
or very comfortable (see Fig 1). Two (13%) subjects
reported discomfort with the 60-mm Hg graduated IPC
profile. These two subjects also reported pain as an
adverse event with this profile. Both adverse events were
categorized as mild in severity, non-serious, and related
to the device, and neither subject reported pain with use
of the device at 40- to 50-mm Hg. No other adverse
Fig 1. Device comfort ratings by pneumatic pressure profile.
Most subjects reported being comfortable or very comfortable
with each pressure profile, and no subject reported being very
uncomfortable. Device comfort ratings were not applicable for the
periods with no treatment. Pressures refer to the pressure admin-
istered at the gaiter. Twelve subjects were treated with each sus-
tained pneumatic compression (SPC) profile for 6 hours, with at
least 48 hours between each profile. Sixteen subjects were treated
with each intermittent pneumatic compression (IPC) profile for
two hours, with at least 46 hours between each profile.events were reported.Evaluations of toe systolic pressure and TcpO2 re-
vealed no negative effects (Table IV). Toe systolic pres-
sure in the test leg increased dose-dependently at 1.5
hours (ie, during graduated IPC or observation only) for
every profile; at 2.5 hours (after treatment), toe systolic
pressure continued to increase in the observation-only
profile, but it returned to near baseline for each of the
graduated IPC profiles. Values for TcpO2 also increased
from baseline during IPC but returned to near baseline
shortly after treatment; IPC did not appear to have a
dose-dependent effect on TcpO2 during or after treat-
ment.
Dose-dependent reductions of leg volume were ob-
served with graduated IPC therapy (Fig 3). Volume of the
test leg increased 19 mL relative to the untreated leg for the
observation-only profile. Relative decreases with active
treatment ranged from 109 mL for 40-mm Hg graduated
IPC to 146 mL for 60-mm Hg graduated IPC. Signifi-
cantly greater (P  .001) reductions in leg volume were
observed with all treatment profiles than with the observa-
tion-only profile.
No subject developed new-onset ankle edema and
several subjects had resolution of ankle edema during
graduated IPC therapy. The resolution of baseline ankle
edema after use of the device appeared to be dose-
dependent, with percent resolution ranging from 27%
for 40-mm Hg graduated IPC to 75% for 60-mm Hg
graduated IPC.
DISCUSSION
In these two physiological phase II clinical studies,
the use of SPC or IPC with a four-chamber pneumatic
compression device was shown to be safe and generally
well tolerated. The safety and tolerability of pneumatic
compression were confirmed by the absence of reported
adverse events for any of the six SPC treatment profiles
and reports of an adverse event (pain with device wear)
by two subjects in the IPC study only at the highest
pressure profile tested (60-mm Hg at the gaiter). There
were no apparent negative effects on toe systolic pressure
and TcpO2 during and after device wear in the IPC
study. These endpoints were not evaluated in the SPC
study, which was conducted before the IPC study. Ad-
ditional study of these endpoints with SPC could provide
valuable information about the safety of sustained com-
pression with respect to foot health.
The main objective of these studies was to examine a
range of pressure profiles and determine the safety and
the relative effects of the different cuff pressure combi-
nations. Reduction of leg edema was dose-dependent for
both SPC and IPC. The most effective reduction of leg
edema in the SPC study was observed with the highest
pressure tested of 40-mm Hg nongraduated SPC (30,
40, 40, and 40-mm Hg at the foot, gaiter, mid-calf, and
upper-calf, respectively), but discomfort was also re-
ported by three subjects with this profile. Use of the
highest pressure at the gaiter, but graduated SPC in the
mpar
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gaiter, mid-calf, and upper-calf, respectively), also re-
duced leg edema and leg circumference substantially but
Fig 2. A, Mean(SEM)absolutechange in legvolumefromb
least-squares mean for the difference between the treated and u
SPC, treated leg vs untreated leg. Pressures for each graduated
gaiter. Treatment with SPC was associated with dose-depende
six-hour observation/treatment period. Twelve subjects were t
each profile. *P value based on least-squares mean, pairwise cowas not associated with any reports of discomfort. Alower pressure of 30-mm Hg at the gaiter (and gradu-
ated or nongraduated SPC) also performed well, with
only one report of discomfort for nongraduated SPC.
e foreachsustainedpneumaticcompression(SPC)profileand
ed legs.B, Mean (SEM) relative reduction in leg volume with
ongraduated profile refer to the pressure administered at the
an reductions of leg volume from the start to the end of each
with each profile for six hours, with at least 48 hours between
ison to no compression.aselin
ntreat
and n
nt me
reatedThe lowest pressure of 20-mm Hg graduated or non-
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for limb volume or circumference reduction. Therefore,
30- to 40-mm Hg graduated SPC or 30-mm Hg non-
graduated SPC seem to be the most promising variants
and deserve further clinical evaluation in the manage-
ment of chronic venous disorders.
In the IPC study, 40-mm Hg graduated IPC was the
most effective profile but was associated with two reports of
discomfort and pain, which were the only reported adverse
events for pneumatic compression in either study. The
30-mm Hg graduated IPC profile performed well without
any reports of discomfort. Resolution of ankle edema from
the start to the end of IPC treatment revealed a pressure-
dependent response, with a rank order of 40-mm Hg
30-mm Hg  20-mm Hg  no compression. No IPC
test profile was associated with new-onset ankle edema
during wear.
Treatment with IPC in the management of CVI and
venous ulcers has been examined for more than 25
years,7 but to our knowledge, no prior study compared
different pressure profiles and reported their relative
safety, tolerability, and effectiveness for edema reduc-
tion. This study supports the hypothesis that higher
pressures reduce edema more effectively than lower pres-
sures. However, the optimal pressure profile may vary
between different devices and should be evaluated for
each device individually, particularly since some pressure
profiles may be associated with discomfort or pain. In
these studies, adverse events were only reported for two
subjects, both of whom had pain with IPC at the highest
pressure tested of 60 mm Hg. It is notable that recently
developed consensus guidelines for compression ban-
dages, not pneumatic compression devices, would place
this pressure between the high pressure range of 40 to 60
mm Hg and the very high pressure range of 60 to 80 mm
Hg. A typical range of pressures for compression ban-
dages and stockings is closer to the medium range of 20
to 40 mm Hg.10 Therefore, although pneumatic com-
Table IV. Change in toe systolic pressure and transcutane
compression for two hours
No IPC
Toe systolic pressure
Change at 1.5 hours* 17.3 (4.9)
Change at 2.5 hours
†
30.1 (12.1)
TcpO2
Change at 1.5 hours* 2.13 (1.62)
Change at 2.5 hours
†
1.06 (1.35)
IPC, intermittent pneumatic compression; TcpO2, transcutaneous oxygen p
*During treatment.
†30 minutes after IPC.pression devices make it possible to exert greater pres-sures, as observed in this study, it is important not to
simply maximize the pressure but to identify the cuff
pressure that achieves the best balance of effectiveness
and tolerability. Additionally, it remains to be deter-
mined whether the different pneumatic compression de-
vices have the same optimal pressure profiles, because
pressures in the cuffs may not be the same as those
measured on the skin.11
In addition to comfort, other considerations that might
influence the choice of one treatment over the other in-
clude the mobility of the patient and the therapeutic aim.
Patients who are ambulatory will have some degree of cyclic
vein compression from the surrounding muscles as they
walk, whereas immobile patients may benefit more from
stimulation of a similar process with IPC. The therapeutic
aim may also influence the strength of compression that is
required. For example, patients who need compression of
leg veins in a standing position may require higher pres-
sures,12 whereas patients who receive pneumatic compres-
sion for the treatment of edema may respond to lower
pressures.
Previous studies evaluated the effect of pneumatic
compression on the rate and extent of healing for venous
ulcers.7 Because that was not a goal of these studies,
patients with open wounds (C6 on the CEAP classifica-
tion13) were excluded. Additional study would be valu-
able to determine the relative safety and performance of
different SPC/IPC pressure profiles for edema reduction
in patients with open wounds. Another potential limita-
tion of this study was the short treatment and follow-up
period for each compression profile. Information about
the return of edema after device removal was not col-
lected and the safety and effects of ongoing treatment
were not evaluated. Additional study of leg volume
during and after 2 to 4 weeks of pneumatic compression
therapy would be welcome.
In summary, SPC and IPC with a pneumatic compres-
sion test device were safe and well-tolerated, with a dose-
response relationship between increased compression and
oxygen pressure with intermittent pneumatic
n (SEM) change from baseline, mm Hg
IPC profile
40 mm Hg 50 mm Hg 60 mm Hg
4.0 (11.3) 25.9 (8.5) 33.8 (8.9)
6.3 (4.1) 2.1 (5.8) 6.4 (4.1)
.88 (1.06) 3.31 (0.97) 2.94 (0.70)
.88 (1.41) 0.00 (0.83) 0.19 (1.05)
e.ous
Mea
2
2
0
ressurreduced leg edema. Based on the combination of tolerabil-
ion.
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SPC, 30-mm Hg nongraduated SPC, and 50-mm Hg
graduated IPC deserve further evaluation in the manage-
Fig 3. A, Mean (SEM) absolute change in leg volume
(IPC) profile and least-squares mean for the difference be
reduction in leg volume with IPC, treated leg vs untreat
least-squares mean for the difference between the treated
dose-dependent mean (SEM) reductions of leg volume
subjects were treated with each profile for 2 hours, wit
least-squares mean, pairwise comparison to no compressment of severe venous disease.The study was supported by ConvaTec, a Division of
E.R. Squibb & Sons, L.L.C., Princeton, NJ, USA. Donalyn
Hyland and Jonathan N. Latham provided writing support
baseline for each intermittent pneumatic compression
the treated and untreated legs. B, Mean (SEM) relative
g. Reported reduction or increase for each profile is the
untreated legs. Treatment with IPC was associated with
the start to the end of each treatment period. Sixteen
east 46 hours between each profile. *P value based onfrom
tween
ed le
and
from
h at lon behalf of ConvaTec.
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Volume 49, Number 2 Vanscheidt et al 402.e1Table III (online only). Change in leg circumference wit
Location
Mean (
No SPC
Graduated SPC
20 mm Hg* 30 mm Hg
Ankle
Treated leg 1.5 (1.49) 5.2 (1.81) 7.5 (1.5
Untreated leg 1.9 (1.72) 2.9 (1.19) 4.6 (1.5
Relative change
†
0.4 (1.92) 8.1 (1.77) 12.1 (2.1
Calf
Treated leg 1.3 (10) 1.5 (1.36) 4.0 (1.2
Untreated leg 2.7 (1.36) 1.9 (1.27) 4.4 (1.0
Relative change
†
1.5 (2.56) 3.3 (1.95) 8.3 (1.8
Tibial Tuberosity
Treated leg 3.5 (1.58) 1.5 (1.64) 0.4 (1.3
Untreated leg 0.2 (0.95) 2.5 (1.38) 4.0 (1.3
Relative change
†
3.3 (1.83) 1.0 (2.49) 4.4 (0.9
Mid-Foot
Treated leg 3.5 (1.09) 0.6 (1.54) 3.1 (1.3
Untreated leg 0.2 (0.95) 4.2 (1.49) 4.2 (1.4
Relative change
†
3.8 (1.17) 4.8 (1.75) 7.3 (2.1
SPC, sustained pneumatic compression.
*Pressure applied at the gaiter; some profiles used different profiles at the fo
†Relative change, treated vs untreated leg.h sustained pneumatic compression for six hours
SEM) change in circumference, mm
profile Nongraduated SPC profile
* 40 mm Hg* 20 mm Hg* 30 mm Hg* 40 mm Hg*
7) 14.8 (3.13) 6.9 (1.51) 10.8 (1.80) 14.4 (1.80)
9) 4.0 (1.70) 1.3 (0.78) 1.5 (1.17) 0.4 (1.40)
3) 18.8 (2.86) 8.1 (1.88) 12.3 (2.21) 14.8 (1.91)
1) 12.9 (2.66) 8.5 (1.13) 15.6 (2.11) 20.6 (1.60)
7) 1.9 (1.51) 1.9 (0.63) 2.5 (1.51) 2.5 (1.38)
5) 14.8 (2.88) 10.4 (1.34) 18.1 (2.61) 23.1 (1.92)
4) 1.3 (1.32) 2.5 (1.63) 2.9 (1.87) 5.4 (2.01)
9) 1.7 (1.32) 1.5 (1.61) 4.0 (1.21) 3.1 (1.16)
8) 2.9 (0.96) 4.0 (2.29) 6.9 (2.43) 8.5 (1.75)
8) 2.1 (0.91) 1.3 (0.84) 1.0 (1.52) 0.4 (1.22)
2) 2.5 (0.97) 3.3 (1.52) 2.5 (1.60) 3.5 (0.95)
4) 4.6 (1.40) 2.1 (1.79) 1.5 (1.75) 3.1 (1.82)
